TICKERNERD
Menu
NBIXNBIXHealthcare · Drug Manufacturers - Specialty & Generic

NBIX Stock Forecast: Neurocrine Biosciences, Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$146
+0.90% on the day

The 29 Wall Street analysts covering Neurocrine Biosciences, Inc. hold a median 12-month price target of $213 — +46.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 6 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$14.8B
Ticker Nerd rank
87 / 100
Median analyst target
$213
Analysts covering
29
Revenue$959.0M+39.5% y/y
Operating income$153.0M
Net income$144.4M
Free cash flow$128.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.2%
1M
−6.5%
YTD
+2.6%
1Y
+4.4%
From 52W high
−21.6%
From 52W low
+18.2%
$123
$186
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NBIX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Neurocrine Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
87 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Quality
97
Volatility
94
Growth
92
Issuance
73
Momentum
60
Revisions
58
Accruals
30
Size
12

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (30): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NBIX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NBIX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$150$200$250Jan 26Apr 26Jul 26Oct 26NBIXHigh $253Median $213Low $164

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says29 analysts
25 Buy4 Hold0 Sell
Low $164Median $213High $253

The green dot is the last close — the median target sits +46.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
6 Oct 2026GuggenheimAssumesBuy$207
29 Sept 2026UBSMaintainsBuy$231 → $214
11 Sept 2026Morgan StanleyMaintainsEqual-Weight$182 → $183
11 Sept 2026Morgan StanleyMaintainsEqual-Weight—
8 Sept 2026RBC CapitalReiteratesOutperform$198
8 Sept 2026RBC CapitalReiteratesOutperform—
3 Sept 2026CitigroupMaintainsBuy—
3 Sept 2026CitigroupMaintainsBuy$249 → $253
13 Aug 2026Morgan StanleyMaintainsEqual-Weight—
13 Aug 2026Morgan StanleyMaintainsEqual-Weight$196 → $182
3 Aug 2026Canaccord GenuityMaintainsBuy$200 → $210
3 Aug 2026Canaccord GenuityMaintainsBuy—
3 Aug 2026Truist SecuritiesMaintainsBuy—
3 Aug 2026Truist SecuritiesMaintainsBuy$200 → $213
3 Aug 2026WedbushMaintainsOutperform$185 → $194
3 Aug 2026WedbushMaintainsOutperform—
31 July 2026Cantor FitzgeraldMaintainsOverweight—
31 July 2026Cantor FitzgeraldMaintainsOverweight$210 → $215
31 July 2026CitigroupMaintainsBuy—
31 July 2026CitigroupMaintainsBuy$246 → $249

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NBIX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NBIX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Neurocrine Biosciences, Inc. returned +4.4% against +17.3% for the S&P 500, dividends included.

NBIX vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130Jan 26Apr 26Jul 26Oct 26NBIXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NBIX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.5%
Analysts raising
2
Analysts cutting
1
Fundamentals

Neurocrine Biosciences, Inc. (NBIX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
21.3×

Cheaper than 35% of US stocks

Price / sales
4.4×

Cheaper than 28% of US stocks

Price / book
4.0×

Cheaper than 25% of US stocks

EV / EBITDA
16.1×

Cheaper than 20% of US stocks

Growth & margins
Revenue growth (YoY)
39.5%

Higher than 83% of US stocks

Earnings growth (YoY)
34.3%

Higher than 68% of US stocks

Gross margin
97.6%

Higher than 99% of US stocks

Operating margin
22.2%

Higher than 81% of US stocks

Net margin
20.9%

Higher than 83% of US stocks

Returns & dividend
Return on equity
22.1%

Higher than 83% of US stocks

Return on assets
11.7%

Higher than 94% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Neurocrine Biosciences, Inc. (NBIX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Neurocrine Biosciences, Inc. has a market value of $14.8B and an enterprise value of $14.7B.

  • Revenue in the twelve months to 30 June 2026: $3.4B. The latest quarter grew 39.5% year on year.

  • Net income over the same four quarters: $705.5M, a 20.9% net margin.

  • Diluted earnings per share, trailing twelve months: $6.82.

  • Free cash flow in the twelve months to 30 June 2026: $870.4M, after $27.7M of capital spending.

  • Neurocrine Biosciences, Inc. spent $66.0M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 101.6M.

  • Trailing P/E: 21.3×; forward P/E: 12.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Neurocrine Biosciences, Inc. employs 2,500 people — $1.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

NBIX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
NBIXNeurocrine Biosciences, Inc.$14.8B
87
ELANElanco Animal Health, Inc.$11.2B
97
VTRSViatris, Inc.$20.2B
100
UTHRUnited Therapeutics Corp.$23.0B
81
ZTSZoetis, Inc.$29.5B
43
ALKSAlkermes Plc$6.9B
61
HIMSHims & Hers Health, Inc.$6.9B
17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Neurocrine Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NBIX news & analysis

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

PRNewsWire · 30 Sept 2026positive

Neurocrine Biosciences announced it will present research at the Foundation for Prader-Willi Research 2026 Annual Research Symposium & Family Conference in Philadelphia, Oct. 7-10. Presentations will include the PWS-VISTA observational study building longitudinal real-world evidence on VYKAT XR for hyperphagia, the BRAVE-PWS study on caregiver burden, and an integrated analysis of adverse events of special interest during VYKAT XR treatment.

Why it matters — The expanded clinical and real-world evidence on VYKAT XR presented at the conference could strengthen understanding and support of a key Neurocrine product in Prader-Willi syndrome.

Neurocrine Biosciences Appoints Eiry W. Roberts, M.D.

PRNewsWire · 28 Sept 2026neutral

Neurocrine Biosciences announced the appointment of Eiry W. Roberts, M.D., as announced via PRNewswire on September 28, 2026. The press release from the San Diego-based company confirms the new appointment.

Why it matters — A leadership appointment could be notable for NBIX watchers as changes in executive roles may influence the company's strategic direction.

Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit

MarketBeat · 23 Sept 2026neutral

During a Morgan Stanley discussion, Neurocrine CEO Kyle Gano outlined the company's commercial growth priorities, pricing considerations, and pipeline plans, emphasizing efforts to diversify beyond its largest product, INGREZZA, which faces a price impact in 2029.

Why it matters — NBIX watchers would care because the company is addressing its heavy reliance on INGREZZA ahead of the 2029 pricing challenge that could affect its revenue base.

Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 16 Sept 2026neutral

Neurocrine Biosciences presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation made available via Seeking Alpha. The item reports that the company participated in this investor conference.

Why it matters — A Neurocrine watcher would care because the company's presentation at a major investment conference offers insight into how it communicates its business to the financial community.

Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Seeking Alpha · 10 Sept 2026neutral

Neurocrine Biosciences presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, with a transcript of the presentation published by Seeking Alpha. The item reports on the company's participation in the conference event.

Why it matters — A NBIX watcher would care because the conference presentation provides an opportunity to hear management's discussion of the company's business and pipeline in a public forum.

FAQ

Frequently asked questions about NBIX stock

What is the NBIX stock price forecast for 2026-2027?

The 29 Wall Street analysts covering Neurocrine Biosciences, Inc. have a median 12-month price target of $213, with estimates ranging from $164 to $253. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NBIX stock a buy right now?

Of the 29 analysts covering Neurocrine Biosciences, Inc., 25 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neurocrine Biosciences, Inc. 87 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NBIX?

As at 6 Oct 2026, Neurocrine Biosciences, Inc. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will NBIX stock go up?

No one can know that. What the data says: the median 12-month target from 29 analysts implies +46.4% from the last close, and Ticker Nerd's factor model ranks Neurocrine Biosciences, Inc. 87 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NBIX stock forecast for 2030?

No analyst covering Neurocrine Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NBIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $164 to $253 over the next 12 months.

How has NBIX stock performed over the past year?

Neurocrine Biosciences, Inc. returned +4.4% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Neurocrine Biosciences, Inc. do?

Neurocrine Biosciences, Inc. is a neuroscience-focused biopharmaceutical company that discovers, develops, and commercializes medicines for neurological, neuroendocrine, and neuropsychiatric disorders.

What is the latest news on NBIX?

The most recent item we track (PRNewsWire, 30 Sept 2026): "Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference". Neurocrine Biosciences announced it will present research at the Foundation for Prader-Willi Research 2026 Annual Research Symposium & Family Conference in Philadelphia, Oct. 7-10. Presentations will include the PWS-VISTA observational study building longitudinal real-world evidence on VYKAT XR for hyperphagia, the BRAVE-PWS study on caregiver burden, and an integrated analysis of adverse events of special interest during VYKAT XR treatment.

Company

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is a neuroscience-focused biopharmaceutical company that discovers, develops, and commercializes medicines for neurological, neuroendocrine, and neuropsychiatric disorders. Its current portfolio includes treatments for movement disorders such as tardive dyskinesia and Huntington’s disease chorea, as well as therapies for endocrine conditions including congenital adrenal hyperplasia, endometriosis, and uterine fibroids. The company also maintains a clinical-stage pipeline spanning additional neuroscience and endocrine targets, with research programs aimed at addressing underserved patient populations. Neurocrine Biosciences, Inc. plays an important role in specialty pharmaceuticals by combining marketed products with ongoing drug development across complex, chronic conditions that often require long-term management. Headquartered in San Diego, California, it serves patients and healthcare providers in the United States and internationally through its commercial operations and development activities.

CEO Mr. Kyle W. Gano Ph.D. · 2,500 employees · United States · https://www.neurocrine.com